A Phase II Trial of Olaparib Plus Pembrolizumab in Patients with Recurrent Copy-Number High/p53-Abnormal Endometrial Cancer
Maria M. Rubinstein·Vicky Makker·Q. Zhou·Alexia Iasonos·B Weigelt·P. Selenica·Daniel M. Muldoon·Chaitanya Bandlamudi·Caitlin Kaczynski·Viktoriya Paroder·Kelsey Higgins·Pooja Shah·S. Weissblum·Aleya Lyn·Y. Liu·Sminu Bose·Seth M. Cohen·Angela K. Green·Rachel N. Grisham·Chrisann Kyi·Roisin E. O'Cearbhaill·William P. Tew·Mike Berger·Carol Aghajanian·Jennifer Y. Ge
The combination of olaparib plus pembrolizumab has promising activity with durable responses in patients with persistent or recurrent CN-H/p53-abnormal endometrial cancer. Molecular biomarkers may be helpful for patient selection in future studies of this combination.